nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—ABCG2—Topotecan—cervical cancer	0.605	0.735	CbGbCtD
Prazosin—ABCB1—Topotecan—cervical cancer	0.218	0.265	CbGbCtD
Prazosin—KCNH6—renal system—cervical cancer	0.00719	0.0492	CbGeAlD
Prazosin—KCNH6—uterus—cervical cancer	0.0064	0.0438	CbGeAlD
Prazosin—KCNH6—female reproductive system—cervical cancer	0.00576	0.0394	CbGeAlD
Prazosin—MT3—lymph node—cervical cancer	0.00473	0.0323	CbGeAlD
Prazosin—ADRA1D—epithelium—cervical cancer	0.00429	0.0294	CbGeAlD
Prazosin—SLC22A2—renal system—cervical cancer	0.00425	0.0291	CbGeAlD
Prazosin—ADRA1B—renal system—cervical cancer	0.00407	0.0278	CbGeAlD
Prazosin—ADRA1D—female reproductive system—cervical cancer	0.00319	0.0218	CbGeAlD
Prazosin—ORM1—endometrium—cervical cancer	0.00317	0.0217	CbGeAlD
Prazosin—SLC22A3—uterine cervix—cervical cancer	0.00307	0.021	CbGeAlD
Prazosin—SLC22A1—renal system—cervical cancer	0.003	0.0205	CbGeAlD
Prazosin—SLC22A3—renal system—cervical cancer	0.00287	0.0196	CbGeAlD
Prazosin—SLC22A3—endometrium—cervical cancer	0.00278	0.019	CbGeAlD
Prazosin—SLC22A3—mammalian vulva—cervical cancer	0.00268	0.0184	CbGeAlD
Prazosin—ORM1—female reproductive system—cervical cancer	0.00263	0.018	CbGeAlD
Prazosin—HTR1A—renal system—cervical cancer	0.00248	0.017	CbGeAlD
Prazosin—ADRA1A—epithelium—cervical cancer	0.00247	0.0169	CbGeAlD
Prazosin—HTR1D—female reproductive system—cervical cancer	0.00238	0.0163	CbGeAlD
Prazosin—KCNH2—uterine cervix—cervical cancer	0.00236	0.0161	CbGeAlD
Prazosin—SLC22A3—female reproductive system—cervical cancer	0.0023	0.0157	CbGeAlD
Prazosin—ADRA1A—renal system—cervical cancer	0.00229	0.0156	CbGeAlD
Prazosin—KCNH2—renal system—cervical cancer	0.00221	0.0151	CbGeAlD
Prazosin—SLC22A1—vagina—cervical cancer	0.00218	0.0149	CbGeAlD
Prazosin—KCNH2—endometrium—cervical cancer	0.00214	0.0146	CbGeAlD
Prazosin—ABCG2—uterine cervix—cervical cancer	0.0021	0.0144	CbGeAlD
Prazosin—SLC22A3—female gonad—cervical cancer	0.00209	0.0143	CbGeAlD
Prazosin—SLC22A3—vagina—cervical cancer	0.00208	0.0142	CbGeAlD
Prazosin—CYP1A1—epithelium—cervical cancer	0.00201	0.0138	CbGeAlD
Prazosin—ABCG2—decidua—cervical cancer	0.002	0.0137	CbGeAlD
Prazosin—CYP1A1—uterine cervix—cervical cancer	0.00199	0.0136	CbGeAlD
Prazosin—KCNH2—uterus—cervical cancer	0.00197	0.0135	CbGeAlD
Prazosin—ABCG2—endometrium—cervical cancer	0.0019	0.013	CbGeAlD
Prazosin—CYP1A1—renal system—cervical cancer	0.00187	0.0128	CbGeAlD
Prazosin—ADRA2A—uterine cervix—cervical cancer	0.00186	0.0127	CbGeAlD
Prazosin—ABCG2—mammalian vulva—cervical cancer	0.00184	0.0126	CbGeAlD
Prazosin—ADRA2A—decidua—cervical cancer	0.00177	0.0121	CbGeAlD
Prazosin—KCNH2—female reproductive system—cervical cancer	0.00177	0.0121	CbGeAlD
Prazosin—ABCG2—uterus—cervical cancer	0.00175	0.012	CbGeAlD
Prazosin—CYP1A1—mammalian vulva—cervical cancer	0.00174	0.0119	CbGeAlD
Prazosin—ADRA2A—endometrium—cervical cancer	0.00168	0.0115	CbGeAlD
Prazosin—CYP1A1—uterus—cervical cancer	0.00166	0.0114	CbGeAlD
Prazosin—ADRA2A—mammalian vulva—cervical cancer	0.00163	0.0111	CbGeAlD
Prazosin—KCNH2—female gonad—cervical cancer	0.00161	0.011	CbGeAlD
Prazosin—KCNH2—vagina—cervical cancer	0.0016	0.0109	CbGeAlD
Prazosin—ADRA2A—uterus—cervical cancer	0.00155	0.0106	CbGeAlD
Prazosin—ORM1—lymph node—cervical cancer	0.00154	0.0105	CbGeAlD
Prazosin—CYP1A1—female reproductive system—cervical cancer	0.00149	0.0102	CbGeAlD
Prazosin—ABCG2—female gonad—cervical cancer	0.00143	0.00979	CbGeAlD
Prazosin—ABCG2—vagina—cervical cancer	0.00142	0.00973	CbGeAlD
Prazosin—ADRA2A—female reproductive system—cervical cancer	0.00139	0.00952	CbGeAlD
Prazosin—CYP1A1—female gonad—cervical cancer	0.00136	0.0093	CbGeAlD
Prazosin—CYP1A1—vagina—cervical cancer	0.00135	0.00924	CbGeAlD
Prazosin—SLC22A3—lymph node—cervical cancer	0.00134	0.0092	CbGeAlD
Prazosin—ADRA2A—female gonad—cervical cancer	0.00127	0.00867	CbGeAlD
Prazosin—ADRA2A—vagina—cervical cancer	0.00126	0.00861	CbGeAlD
Prazosin—ABCB1—epithelium—cervical cancer	0.00104	0.00714	CbGeAlD
Prazosin—ABCB1—uterine cervix—cervical cancer	0.00104	0.00708	CbGeAlD
Prazosin—KCNH2—lymph node—cervical cancer	0.00103	0.00708	CbGeAlD
Prazosin—ABCB1—decidua—cervical cancer	0.000987	0.00675	CbGeAlD
Prazosin—ABCB1—renal system—cervical cancer	0.000969	0.00663	CbGeAlD
Prazosin—ABCB1—endometrium—cervical cancer	0.000937	0.00641	CbGeAlD
Prazosin—ABCG2—lymph node—cervical cancer	0.000921	0.0063	CbGeAlD
Prazosin—ABCB1—mammalian vulva—cervical cancer	0.000906	0.0062	CbGeAlD
Prazosin—CYP1A1—lymph node—cervical cancer	0.000874	0.00598	CbGeAlD
Prazosin—ABCB1—uterus—cervical cancer	0.000863	0.0059	CbGeAlD
Prazosin—ADRA2A—lymph node—cervical cancer	0.000815	0.00557	CbGeAlD
Prazosin—ABCB1—female reproductive system—cervical cancer	0.000776	0.00531	CbGeAlD
Prazosin—ABCB1—female gonad—cervical cancer	0.000706	0.00483	CbGeAlD
Prazosin—ABCB1—vagina—cervical cancer	0.000702	0.0048	CbGeAlD
Prazosin—ABCG2—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.00049	0.0163	CbGpPWpGaD
Prazosin—ADRA1D—G alpha (12/13) signalling events—AKAP13—cervical cancer	0.000469	0.0156	CbGpPWpGaD
Prazosin—CYP1A1—Tryptophan metabolism—UBE3A—cervical cancer	0.000462	0.0154	CbGpPWpGaD
Prazosin—ABCB1—lymph node—cervical cancer	0.000454	0.0031	CbGeAlD
Prazosin—KCNH2—Hematopoietic Stem Cell Differentiation—NOTCH1—cervical cancer	0.000404	0.0134	CbGpPWpGaD
Prazosin—ADRA2B—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.000393	0.0131	CbGpPWpGaD
Prazosin—ADRA1B—G alpha (12/13) signalling events—AKAP13—cervical cancer	0.000389	0.013	CbGpPWpGaD
Prazosin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000383	0.0127	CbGpPWpGaD
Prazosin—ABCG2—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000346	0.0115	CbGpPWpGaD
Prazosin—ADRA1A—G alpha (12/13) signalling events—AKAP13—cervical cancer	0.000346	0.0115	CbGpPWpGaD
Prazosin—ADRA2B—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.000344	0.0114	CbGpPWpGaD
Prazosin—ADRA2A—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.000298	0.00992	CbGpPWpGaD
Prazosin—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000265	0.00881	CbGpPWpGaD
Prazosin—ADRA2A—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.000261	0.00867	CbGpPWpGaD
Prazosin—HTR1D—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000255	0.00848	CbGpPWpGaD
Prazosin—CYP1A1—Estrogen Receptor Pathway—STAT3—cervical cancer	0.000246	0.00817	CbGpPWpGaD
Prazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000218	0.00726	CbGpPWpGaD
Prazosin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.000204	0.0068	CbGpPWpGaD
Prazosin—ADRA2B—Hemostasis—SERPIND1—cervical cancer	0.000203	0.00674	CbGpPWpGaD
Prazosin—ADRA2B—Hemostasis—GP6—cervical cancer	0.000203	0.00674	CbGpPWpGaD
Prazosin—ABCG2—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000198	0.00659	CbGpPWpGaD
Prazosin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000197	0.00655	CbGpPWpGaD
Prazosin—HTR1D—GPCR ligand binding—TAAR6—cervical cancer	0.000194	0.00646	CbGpPWpGaD
Prazosin—HTR1A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00019	0.00633	CbGpPWpGaD
Prazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000181	0.00603	CbGpPWpGaD
Prazosin—KCNH2—SIDS Susceptibility Pathways—HES1—cervical cancer	0.00018	0.00599	CbGpPWpGaD
Prazosin—ADRA2B—Hemostasis—GP5—cervical cancer	0.000177	0.00589	CbGpPWpGaD
Prazosin—ADRA1D—GPCR ligand binding—TAAR6—cervical cancer	0.000166	0.00553	CbGpPWpGaD
Prazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000161	0.00535	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—GP6—cervical cancer	0.000154	0.00511	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—SERPIND1—cervical cancer	0.000154	0.00511	CbGpPWpGaD
Prazosin—HTR1D—GPCR ligand binding—WNT2—cervical cancer	0.000152	0.00504	CbGpPWpGaD
Prazosin—ADRA2B—GPCR ligand binding—TAAR6—cervical cancer	0.00015	0.00499	CbGpPWpGaD
Prazosin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00015	0.00497	CbGpPWpGaD
Prazosin—HTR1A—GPCR ligand binding—TAAR6—cervical cancer	0.000145	0.00482	CbGpPWpGaD
Prazosin—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.000143	0.00475	CbGpPWpGaD
Prazosin—ADRA1B—GPCR ligand binding—TAAR6—cervical cancer	0.000138	0.00459	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—GP5—cervical cancer	0.000134	0.00447	CbGpPWpGaD
Prazosin—ABCG2—Fluoropyrimidine Activity—TP53—cervical cancer	0.000131	0.00437	CbGpPWpGaD
Prazosin—ADRA1D—GPCR ligand binding—WNT2—cervical cancer	0.00013	0.00432	CbGpPWpGaD
Prazosin—ADRA1A—GPCR ligand binding—TAAR6—cervical cancer	0.000123	0.00408	CbGpPWpGaD
Prazosin—ADRA2B—GPCR ligand binding—WNT2—cervical cancer	0.000117	0.0039	CbGpPWpGaD
Prazosin—ADRA1B—AMPK Signaling—MTOR—cervical cancer	0.000117	0.00389	CbGpPWpGaD
Prazosin—KCNH7—Circadian rythm related genes—TP53—cervical cancer	0.000116	0.00386	CbGpPWpGaD
Prazosin—HTR1D—GPCR ligand binding—WNT5A—cervical cancer	0.000115	0.00382	CbGpPWpGaD
Prazosin—ADRA1B—LPA receptor mediated events—CASP3—cervical cancer	0.000114	0.0038	CbGpPWpGaD
Prazosin—ADRA2A—GPCR ligand binding—TAAR6—cervical cancer	0.000114	0.00379	CbGpPWpGaD
Prazosin—HTR1A—GPCR ligand binding—WNT2—cervical cancer	0.000113	0.00376	CbGpPWpGaD
Prazosin—HTR1A—SIDS Susceptibility Pathways—HES1—cervical cancer	0.000113	0.00376	CbGpPWpGaD
Prazosin—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	0.000111	0.00371	CbGpPWpGaD
Prazosin—HTR1D—GPCR downstream signaling—TAAR6—cervical cancer	0.00011	0.00365	CbGpPWpGaD
Prazosin—ADRA1B—GPCR ligand binding—WNT2—cervical cancer	0.000108	0.00358	CbGpPWpGaD
Prazosin—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000107	0.00356	CbGpPWpGaD
Prazosin—ADRA1A—AMPK Signaling—MTOR—cervical cancer	0.000104	0.00346	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—TAAR6—cervical cancer	9.97e-05	0.00331	CbGpPWpGaD
Prazosin—ADRA1D—GPCR ligand binding—WNT5A—cervical cancer	9.83e-05	0.00327	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	9.62e-05	0.0032	CbGpPWpGaD
Prazosin—ADRA1A—GPCR ligand binding—WNT2—cervical cancer	9.57e-05	0.00318	CbGpPWpGaD
Prazosin—ADRA1D—GPCR downstream signaling—TAAR6—cervical cancer	9.39e-05	0.00312	CbGpPWpGaD
Prazosin—KCNH2—SIDS Susceptibility Pathways—CASP3—cervical cancer	9.38e-05	0.00312	CbGpPWpGaD
Prazosin—KCNH2—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	9.04e-05	0.00301	CbGpPWpGaD
Prazosin—ADRA2A—GPCR ligand binding—WNT2—cervical cancer	8.89e-05	0.00296	CbGpPWpGaD
Prazosin—ADRA2B—GPCR ligand binding—WNT5A—cervical cancer	8.88e-05	0.00295	CbGpPWpGaD
Prazosin—ADRA1B—LPA receptor mediated events—EGFR—cervical cancer	8.73e-05	0.0029	CbGpPWpGaD
Prazosin—HTR1A—GPCR ligand binding—WNT5A—cervical cancer	8.57e-05	0.00285	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—TAAR6—cervical cancer	8.53e-05	0.00284	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—TAAR6—cervical cancer	8.48e-05	0.00282	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—TAAR6—cervical cancer	8.19e-05	0.00272	CbGpPWpGaD
Prazosin—ADRA1B—GPCR ligand binding—WNT5A—cervical cancer	8.16e-05	0.00271	CbGpPWpGaD
Prazosin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	8.12e-05	0.0027	CbGpPWpGaD
Prazosin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	8.12e-05	0.0027	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—TAAR6—cervical cancer	7.8e-05	0.00259	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—WNT2—cervical cancer	7.78e-05	0.00259	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—TAAR6—cervical cancer	7.7e-05	0.00256	CbGpPWpGaD
Prazosin—HTR1D—GPCR downstream signaling—AKAP13—cervical cancer	7.52e-05	0.0025	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—TAAR6—cervical cancer	7.43e-05	0.00247	CbGpPWpGaD
Prazosin—ABCB1—Allograft Rejection—CASP8—cervical cancer	7.28e-05	0.00242	CbGpPWpGaD
Prazosin—ADRA1A—GPCR ligand binding—WNT5A—cervical cancer	7.25e-05	0.00241	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—TAAR6—cervical cancer	7.08e-05	0.00235	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—TAAR6—cervical cancer	6.93e-05	0.0023	CbGpPWpGaD
Prazosin—ADRA1B—AMPK Signaling—TP53—cervical cancer	6.9e-05	0.00229	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—AKAP13—cervical cancer	6.83e-05	0.00227	CbGpPWpGaD
Prazosin—ADRA2A—GPCR ligand binding—WNT5A—cervical cancer	6.74e-05	0.00224	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—WNT2—cervical cancer	6.66e-05	0.00221	CbGpPWpGaD
Prazosin—ADRA1D—GPCR downstream signaling—AKAP13—cervical cancer	6.44e-05	0.00214	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—TAAR6—cervical cancer	6.43e-05	0.00214	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—TAAR6—cervical cancer	6.29e-05	0.00209	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—CA9—cervical cancer	6.14e-05	0.00204	CbGpPWpGaD
Prazosin—ADRA1A—AMPK Signaling—TP53—cervical cancer	6.13e-05	0.00204	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—WNT2—cervical cancer	6.01e-05	0.002	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—WNT5A—cervical cancer	5.9e-05	0.00196	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TAAR6—cervical cancer	5.89e-05	0.00196	CbGpPWpGaD
Prazosin—HTR1A—SIDS Susceptibility Pathways—CASP3—cervical cancer	5.88e-05	0.00196	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—AKAP13—cervical cancer	5.85e-05	0.00194	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—TAAR6—cervical cancer	5.84e-05	0.00194	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—AKAP13—cervical cancer	5.81e-05	0.00193	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—WNT2—cervical cancer	5.8e-05	0.00193	CbGpPWpGaD
Prazosin—HTR1A—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	5.67e-05	0.00189	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—AKAP13—cervical cancer	5.61e-05	0.00187	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—WNT2—cervical cancer	5.53e-05	0.00184	CbGpPWpGaD
Prazosin—ABCB1—Allograft Rejection—CASP3—cervical cancer	5.51e-05	0.00183	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—AKAP13—cervical cancer	5.34e-05	0.00178	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—AKAP13—cervical cancer	5.28e-05	0.00176	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—AKAP13—cervical cancer	5.1e-05	0.00169	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—WNT5A—cervical cancer	5.05e-05	0.00168	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TAAR6—cervical cancer	5.04e-05	0.00168	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—WNT2—cervical cancer	4.91e-05	0.00163	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—AKAP13—cervical cancer	4.85e-05	0.00161	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—AKAP13—cervical cancer	4.75e-05	0.00158	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—WNT2—cervical cancer	4.6e-05	0.00153	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—WNT2—cervical cancer	4.56e-05	0.00152	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—WNT5A—cervical cancer	4.56e-05	0.00152	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TAAR6—cervical cancer	4.55e-05	0.00151	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—AKAP13—cervical cancer	4.41e-05	0.00147	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—WNT5A—cervical cancer	4.4e-05	0.00146	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TAAR6—cervical cancer	4.39e-05	0.00146	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—AKAP13—cervical cancer	4.31e-05	0.00143	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—WNT5A—cervical cancer	4.19e-05	0.00139	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TAAR6—cervical cancer	4.18e-05	0.00139	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—AKAP13—cervical cancer	4.04e-05	0.00134	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—AKAP13—cervical cancer	4e-05	0.00133	CbGpPWpGaD
Prazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	3.99e-05	0.00133	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—WNT2—cervical cancer	3.93e-05	0.00131	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—CA9—cervical cancer	3.89e-05	0.00129	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—CA9—cervical cancer	3.85e-05	0.00128	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—WNT5A—cervical cancer	3.72e-05	0.00124	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TAAR6—cervical cancer	3.71e-05	0.00124	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	3.59e-05	0.0012	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—CA9—cervical cancer	3.59e-05	0.00119	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—WNT2—cervical cancer	3.55e-05	0.00118	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—WNT5A—cervical cancer	3.48e-05	0.00116	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—WNT5A—cervical cancer	3.46e-05	0.00115	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—AKAP13—cervical cancer	3.45e-05	0.00115	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TAAR6—cervical cancer	3.45e-05	0.00115	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—WNT2—cervical cancer	3.43e-05	0.00114	CbGpPWpGaD
Prazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	3.31e-05	0.0011	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—WNT2—cervical cancer	3.26e-05	0.00109	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—AKAP13—cervical cancer	3.12e-05	0.00104	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—CA9—cervical cancer	3.04e-05	0.00101	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AKAP13—cervical cancer	3.01e-05	0.001	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—WNT5A—cervical cancer	2.98e-05	0.000992	CbGpPWpGaD
Prazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	2.94e-05	0.000978	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—WNT2—cervical cancer	2.9e-05	0.000965	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AKAP13—cervical cancer	2.87e-05	0.000953	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.72e-05	0.000904	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—WNT2—cervical cancer	2.69e-05	0.000896	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—WNT5A—cervical cancer	2.69e-05	0.000895	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—CA9—cervical cancer	2.63e-05	0.000876	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	2.62e-05	0.000872	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—WNT5A—cervical cancer	2.6e-05	0.000864	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKAP13—cervical cancer	2.55e-05	0.000847	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—MTHFR—cervical cancer	2.49e-05	0.000829	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—WNT5A—cervical cancer	2.47e-05	0.000823	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NOTCH2—cervical cancer	2.44e-05	0.000813	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKAP13—cervical cancer	2.37e-05	0.000787	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—WNT5A—cervical cancer	2.2e-05	0.000731	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CA9—cervical cancer	2.1e-05	0.0007	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NOTCH2—cervical cancer	2.09e-05	0.000696	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	2.08e-05	0.000691	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—WNT5A—cervical cancer	2.04e-05	0.000679	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—HES1—cervical cancer	2e-05	0.000667	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NOTCH2—cervical cancer	1.89e-05	0.000628	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NOTCH2—cervical cancer	1.82e-05	0.000607	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TERT—cervical cancer	1.76e-05	0.000584	CbGpPWpGaD
Prazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.74e-05	0.00058	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NOTCH2—cervical cancer	1.74e-05	0.000578	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—HES1—cervical cancer	1.72e-05	0.000571	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—FGFR3—cervical cancer	1.61e-05	0.000536	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—MTHFR—cervical cancer	1.58e-05	0.000525	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—MTHFR—cervical cancer	1.56e-05	0.00052	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HES1—cervical cancer	1.55e-05	0.000515	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NOTCH2—cervical cancer	1.54e-05	0.000513	CbGpPWpGaD
Prazosin—ADRA2B—Hemostasis—TP53—cervical cancer	1.52e-05	0.000507	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NOTCH1—cervical cancer	1.51e-05	0.000503	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TERT—cervical cancer	1.5e-05	0.0005	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HES1—cervical cancer	1.5e-05	0.000497	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—MTHFR—cervical cancer	1.46e-05	0.000485	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NOTCH2—cervical cancer	1.43e-05	0.000477	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HES1—cervical cancer	1.42e-05	0.000474	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—FGFR3—cervical cancer	1.38e-05	0.000459	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TERT—cervical cancer	1.36e-05	0.000451	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—EGFR—cervical cancer	1.35e-05	0.000448	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TERT—cervical cancer	1.31e-05	0.000436	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NOTCH1—cervical cancer	1.3e-05	0.000431	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HES1—cervical cancer	1.26e-05	0.000421	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TERT—cervical cancer	1.25e-05	0.000415	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—FGFR3—cervical cancer	1.25e-05	0.000414	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—MTHFR—cervical cancer	1.23e-05	0.000411	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—FGFR3—cervical cancer	1.2e-05	0.0004	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HES1—cervical cancer	1.18e-05	0.000391	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NOTCH1—cervical cancer	1.17e-05	0.000389	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—TP53—cervical cancer	1.16e-05	0.000385	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—EGFR—cervical cancer	1.15e-05	0.000384	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—FGFR3—cervical cancer	1.14e-05	0.000381	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MTOR—cervical cancer	1.13e-05	0.000377	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NOTCH1—cervical cancer	1.13e-05	0.000375	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TERT—cervical cancer	1.11e-05	0.000369	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NOTCH1—cervical cancer	1.07e-05	0.000358	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—MTHFR—cervical cancer	1.07e-05	0.000356	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CASP3—cervical cancer	1.04e-05	0.000347	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—EGFR—cervical cancer	1.04e-05	0.000346	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TERT—cervical cancer	1.03e-05	0.000342	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—FGFR3—cervical cancer	1.02e-05	0.000338	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—EGFR—cervical cancer	1.01e-05	0.000334	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CTNNB1—cervical cancer	1.01e-05	0.000334	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MTOR—cervical cancer	9.71e-06	0.000323	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—EGFR—cervical cancer	9.58e-06	0.000319	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NOTCH1—cervical cancer	9.55e-06	0.000318	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—FGFR3—cervical cancer	9.45e-06	0.000314	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CASP3—cervical cancer	8.93e-06	0.000297	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NOTCH1—cervical cancer	8.87e-06	0.000295	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—STAT3—cervical cancer	8.76e-06	0.000291	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MTOR—cervical cancer	8.76e-06	0.000291	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CTNNB1—cervical cancer	8.6e-06	0.000286	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—MTHFR—cervical cancer	8.54e-06	0.000284	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—EGFR—cervical cancer	8.51e-06	0.000283	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MTOR—cervical cancer	8.46e-06	0.000281	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CASP3—cervical cancer	8.06e-06	0.000268	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MTOR—cervical cancer	8.06e-06	0.000268	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—EGFR—cervical cancer	7.96e-06	0.000265	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—EGFR—cervical cancer	7.9e-06	0.000263	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CASP3—cervical cancer	7.78e-06	0.000259	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CTNNB1—cervical cancer	7.77e-06	0.000258	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—STAT3—cervical cancer	7.5e-06	0.000249	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CTNNB1—cervical cancer	7.5e-06	0.000249	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CASP3—cervical cancer	7.41e-06	0.000246	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MTOR—cervical cancer	7.15e-06	0.000238	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CTNNB1—cervical cancer	7.14e-06	0.000238	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EGFR—cervical cancer	6.82e-06	0.000227	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—STAT3—cervical cancer	6.77e-06	0.000225	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—cervical cancer	6.69e-06	0.000222	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MTOR—cervical cancer	6.65e-06	0.000221	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CASP3—cervical cancer	6.58e-06	0.000219	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—STAT3—cervical cancer	6.54e-06	0.000217	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CTNNB1—cervical cancer	6.34e-06	0.000211	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—STAT3—cervical cancer	6.23e-06	0.000207	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EGFR—cervical cancer	6.15e-06	0.000205	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CASP3—cervical cancer	6.11e-06	0.000203	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EGFR—cervical cancer	5.94e-06	0.000198	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CTNNB1—cervical cancer	5.89e-06	0.000196	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—cervical cancer	5.72e-06	0.00019	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EGFR—cervical cancer	5.66e-06	0.000188	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—STAT3—cervical cancer	5.53e-06	0.000184	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—cervical cancer	5.17e-06	0.000172	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—STAT3—cervical cancer	5.14e-06	0.000171	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EGFR—cervical cancer	5.03e-06	0.000167	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—cervical cancer	4.99e-06	0.000166	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—cervical cancer	4.75e-06	0.000158	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGFR—cervical cancer	4.67e-06	0.000155	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—cervical cancer	4.22e-06	0.00014	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—cervical cancer	3.92e-06	0.00013	CbGpPWpGaD
